ATOS | tickerfilter.com

Fundamental analysis

21%

Profitability 0%

Dept financing 2%

Liquidity 50%

Performance 40%

Company vs Stock growth

N/A

1.500 0.724

-0.776 -51.75%

+ Add row to compare

Performance

5 Days

-1.66%

1 Month

-20.23%

3 Months

-34.59%

6 Months

-57.78%

1 Year

-67.88%

2 Year

-16.22%

Key data

Stock price

$0.59

P/E Ratio

0.00

DAY RANGE

$0.58 - $0.68

EPS

-$0.20

52 WEEK RANGE

$0.55 - $1.84

52 WEEK CHANGE

-$66.22

MARKET CAP

118.769 M

YIELD

N/A

SHARES OUTSTANDING

125.757 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

2.52

PUBLIC FLOAT

AVERAGE 10 VOLUME

$861,278

AVERAGE 30 VOLUME

$656,340

Company detail

CEO: Steven C. Quay
Region: US
Website: atossatherapeutics.com
Employees: 8
IPO year: 2012

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Atossa Therapeutics, Inc. focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxefen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized patients.

ATOS - ATOSSA THERAPEUTICS, INC.